Drug intelligence / Profile preview

exendin (9-39) + intraduodenal nutrient

Development stage
Unknown
Lead developer
Eiger BioPharmaceuticals
Modality
Peptides
Administration
Intravenous, Oral
01

Overview

Exendin (9-39) is a 31-amino acid peptide that acts as a potent and selective competitive antagonist of the glucagon-like peptide-1 (GLP-1) receptor. It is a truncated version of exendin-4, originally isolated from the venom of the Gila monster (*Heloderma suspectum*). In clinical research, specifically in studies conducted by University Hospital Basel, exendin (9-39) is utilized as a pharmacological probe to investigate the physiological role of endogenous GLP-1 in appetite regulation and glucose metabolism. The combination with intraduodenal (ID) nutrient infusion allows researchers to stimulate the natural release of GLP-1 from the gut and subsequently block its effects to measure its contribution to satiety and gastric emptying. This experimental paradigm is primarily used in Phase 1 physiological studies to understand the mechanisms of obesity and eating behavior.

Other names
exendin (9-39) + ID nutrientGLP-1 receptor antagonist + intraduodenal nutrient
02

Targets

Beyond the preview

Go deeper on exendin (9-39) + intraduodenal nutrient.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on exendin (9-39) + intraduodenal nutrient.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call